2028 Healthcare Prescription 
World of DTC Marketing
SEPTEMBER 9, 2021
SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. Prescription drug costs are only a small part of healthcare costs, and by 2028 U.S. healthcare spending will reach $6.2
World of DTC Marketing
APRIL 7, 2022
Right now, voters are worried about inflation and rising fuel prices, but they ignore the imminent threats to their healthcare. American healthcare continues to be under assault, and unless we address these issues, a severe health issue could bankrupt families. THREAT 3: RISING HEALTHCARE COSTS. THREAT 1: OBESITY AND DIABETES.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
World of DTC Marketing
JULY 28, 2022
Nationwide, prescription drug spending last year is estimated to be $328 billion among all payers, including private insurance, Medicare Part D, and patients’ out-of-pocket expenses. Nearly 9 in 10 older adults take prescription medication. Still, the pharma industry is fighting hard to keep it off the table.
World of DTC Marketing
MARCH 17, 2021
A great example of pharma’s profiteering is biosimilar drugs which cost a lot and add billions of dollars to healthcare costs. Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028. Political pressure was mounting in the US, the most profitable market.
Nixon Gwilt Law
MAY 26, 2023
As a law firm focused specifically on healthcare innovation, we get really excited about developing areas of the healthcare industry. Digital health companies building VR solutions often ask us this question, and if you are a founder or executive looking for ways to commercialize your VR platform for healthcare providers in the U.S.,
PM360
SEPTEMBER 21, 2023
As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. CMS negotiation may lead to additional savings for beneficiaries and for the Medicare program.
Clarivate
OCTOBER 25, 2023
While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. With 27.5%
Expert insights. Personalized for you.
222 
Let's personalize your content